Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells

BackgroundUDP-glucuronosyltransferase 1A1 (UGT1A1) is a pivotal enzyme involved in metabolism of SN-38, the active metabolite of irinotecan commonly used to treat metastatic colorectal cancer. We previously demonstrated aberrant methylation of specific CpG dinucleotides in UGT1A1-negative cells, and revealed that methylation state of the UGT1A1 5'-flanking sequence is negatively correlated with gene transcription. Interestingly, one of these CpG dinucleotides (CpG -4) is found close to a HNF1 response element (HRE), known to be involved in activation of UGT1A1 gene expression, and within an upstream stimulating factor (USF) binding site.ResultsGel retardation assays revealed that methylation of CpG-4 directly affect the interaction of USF1/2 with its cognate sequence without altering the binding for HNF1-alpha. Luciferase assays sustained a role for USF1/2 and HNF1-alpha in UGT1A1 regulation in colon cancer cells. Based on the differential expression profiles of HNF1A gene in colon cell lines, we also assessed whether methylation affects its expression. In agreement with the presence of CpG islands in the HNF1A promoter, treatments of UGT1A1-negative HCT116 colon cancer cells with a DNA methyltransferase inhibitor restore HNF1A gene expression, as observed for UGT1A1.ConclusionsThis study reveals that basal UGT1A1 expression in colon cells is positively regulated by HNF1-alpha and USF, and negatively regulated by DNA methylation. Besides, DNA methylation of HNF1A could also play an important role in regulating additional cellular drug metabolism and transporter pathways. This process may contribute to determine local inactivation of drugs such as the anticancer agent SN-38 by glucuronidation and define tumoral response.

[1]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[2]  A. Rizzino,et al.  Transcriptional Regulation of the Transforming Growth Factor-β2 Promoter by cAMP-responsive Element-binding Protein (CREB) and Activating Transcription Factor-1 (ATF-1) Is Modulated by Protein Kinases and the Coactivators p300 and CREB-binding Protein* , 1999, The Journal of Biological Chemistry.

[3]  P. Mackenzie,et al.  Liver-enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression. , 2008, Current drug metabolism.

[4]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[5]  S. Cereghini.  Liver‐enriched transcription factors and hepatocyte differentiation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  C. Vinson,et al.  The IGF2 Receptor Is a USF2-specific Target in Nontumorigenic Mammary Epithelial Cells but Not in Breast Cancer Cells* , 2003, Journal of Biological Chemistry.

[7]  F. Watt,et al.  Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. , 1988, Genes & development.

[8]  C. Guillemette,et al.  Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer , 2006, Clinical Cancer Research.

[9]  S. Vaulont,et al.  Proteins binding to the liver-specific pyruvate kinase gene promoter. A unique combination of known factors. , 1989, Journal of molecular biology.

[10]  L. Quattrochi,et al.  Characterization of adjacent E‐box and nuclear factor 1‐like DNA binding sequence in the human CYP1A2 promoter , 2005, Journal of biochemical and molecular toxicology.

[11]  M. Houde,et al.  Intestinal Epithelial Cell Differentiation Involves Activation of p38 Mitogen-activated Protein Kinase That Regulates the Homeobox Transcription Factor CDX2* , 2001, The Journal of Biological Chemistry.

[12]  Yoshiro Saito,et al.  Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  G. Prendergast,et al.  Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. , 1991, Science.

[14]  S. Clark,et al.  Sp1 binding is inhibited by (m)Cp(m)CpG methylation. , 1997, Gene.

[15]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[16]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[17]  J. S. Macpherson,et al.  Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. , 2002, Biochemical pharmacology.

[18]  C. Allis,et al.  Epigenetics: A Landscape Takes Shape , 2007, Cell.

[19]  K. Gaston,et al.  CpG methylation has differential effects on the binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes. , 1995, Nucleic acids research.

[20]  R. Roeder,et al.  Multiple forms of the human gene-specific transcription factor USF. I. Complete purification and identification of USF from HeLa cell nuclei. , 1988, The Journal of biological chemistry.

[21]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[22]  P. Mackenzie,et al.  Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4&agr; , 2007, Pharmacogenetics and genomics.

[23]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Manns,et al.  Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. , 1998, Molecular pharmacology.

[25]  P. Laird.  Cancer epigenetics. , 2005, Human molecular genetics.

[26]  C. Guillemette,et al.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.

[27]  P. A. Gregory,et al.  Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter. , 2000, Pharmacogenetics.

[28]  M. Sawadogo.  Multiple forms of the human gene-specific transcription factor USF. II. DNA binding properties and transcriptional activity of the purified HeLa USF. , 1988, The Journal of biological chemistry.

[29]  C. Brown,et al.  Regulation of human alcohol dehydrogenase genes. , 1992, Pharmacogenetics.

[30]  B. Chatterjee,et al.  Tissue-specific and Androgen-repressible Regulation of the Rat Dehydroepiandrosterone Sulfotransferase Gene Promoter* , 1998, The Journal of Biological Chemistry.

[31]  P. A. Gregory,et al.  Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. , 2004, Toxicology and applied pharmacology.

[32]  M. Watson,et al.  Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer , 2005, Clinical Cancer Research.

[33]  S. Clark,et al.  Sp1 binding is inhibited by mCpmCpG methylation , 1997 .

[34]  P. A. Gregory,et al.  Regulation of UDP glucuronosyltransferase genes. , 2003, Current drug metabolism.

[35]  P. Sharp,et al.  A single polypeptide possesses the binding and transcription activities of the adenovirus major late transcription factor , 1986, Molecular and Cellular Biology.

[36]  Ashok Kumar,et al.  HNF-1alpha plays an important role in IL-6-induced expression of the human angiotensinogen gene. , 2007, American journal of physiology. Cell physiology.

[37]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[38]  P. Mackenzie,et al.  Isolation of the UDP-Glucuronosyltransferase 1A3 and 1A4 Proximal Promoters and Characterization of Their Dependence on the Transcription Factor Hepatocyte Nuclear Factor 1α , 2007, Drug Metabolism and Disposition.

[39]  R. Roeder,et al.  Interaction of a gene-specific transcription factor with the adenovirus major late promoter upstream of the TATA box region , 1985, Cell.

[40]  Yusuke Nakamura,et al.  Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas , 2002, Oncogene.

[41]  J. Darnell,et al.  Analysis of the upstream elements of the xenobiotic compound-inducible and positionally regulated glutathione S-transferase Ya gene , 1990, Molecular and cellular biology.

[42]  P. Mackenzie,et al.  Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. , 2000, Molecular pharmacology.

[43]  B. Kirschbaum,et al.  Definition of the transcriptional activation domain of recombinant 43-kilodalton USF , 1992, Molecular and cellular biology.

[44]  David A Jones,et al.  Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.

[45]  B. Desvergne,et al.  Activation of the mouse TATA-less and human TATA-containing UDP-glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1. , 1999, Molecular pharmacology.

[46]  M. Klemsz,et al.  Methylation of an ETS site in the intron enhancer of the keratin 18 gene participates in tissue-specific repression , 1997, Molecular and cellular biology.

[47]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[48]  司履生.  Cancer epigenetics , 2006 .

[49]  Yuzhuo Wang,et al.  Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation , 2007, Cancer Cell International.

[50]  J. Robert,et al.  Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. , 1998, Cancer research.

[51]  P. A. Gregory,et al.  Identification and characterization of functional hepatocyte nuclear factor 1-binding sites in UDP-glucuronosyltransferase genes. , 2005, Methods in enzymology.

[52]  J. Ritter,et al.  Involvement of hepatocyte nuclear factor 1 in the regulation of the UDP-glucuronosyltransferase 1A7 (UGT1A7) gene in rat hepatocytes. , 2000, Molecular pharmacology.

[53]  P. A. Gregory,et al.  Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2. , 2004, Molecular pharmacology.

[54]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.